Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update

– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30...
April 29, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021

DURHAM, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
April 26, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix Appoints Vicki Vakiener to Board of Directors

DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
April 08, 2021 16:01 ET | Source: Chimerix, Inc.

Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
March 02, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
February 25, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT

– Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to...
February 25, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix Reports Fourth Quarter and Year End 2020 Financial Results and Provides Operational Update

– Acquisition of Oncoceutics Adds Late-Stage Precision Oncology Pipeline – – Recently Completed Financing Supports Broad Investment Across Pipeline – – Conference Call at 8:30 a.m....
February 18, 2021 07:00 ET | Source: Chimerix, Inc.

Chimerix to Report Fourth Quarter and Year End 2020 Financial Results and Provide an Operational Update on February 25, 2021

DURHAM, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
January 25, 2021 17:44 ET | Source: Chimerix, Inc.

Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
January 20, 2021 20:03 ET | Source: Chimerix, Inc.

Chimerix Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right